In mantle cell lymphoma, ibrutinib-resistant patients show recurrent mutations in TRAF2 or BIRC3 associated with constitutive non-canonical NF-κB signaling and a complete dependence on NIK (49). Here, MAP3K14 is linked to mantle cell lymphoma.